AstraZeneca AB & Anr. v. USV Private Limited

Patent wars between multinational pharmaceutical giants and domestic generic manufacturers are often portrayed as epic, winner-takes-all courtroom dramas. But sometimes, the most powerful move a company can make is to step away from the battlefield and sign on the dotted line. The dispute between AstraZeneca AB and USV Private Limited is a textbook example of how a patent infringement suit can transform from a costly legal quagmire into a strategic, court-enforced settlement — and why founders and IP professionals should pay close attention to the mechanics of compromise.

AstraZeneca AB, a global pharmaceutical powerhouse, filed a suit for permanent injunction against USV Private Limited, an Indian pharmaceutical company, alleging infringement of Indian Patent Nos. 205147 and 235625. These patents represented valuable intellectual property assets that AstraZeneca sought to protect from alleged unauthorized use. The dispute had already seen prior litigation activity, with USV having been awarded costs of Rs. 5 lakhs in its favour in FAO(OS)(COMM) No. 157/2020. As the infringement suit progressed through the Delhi High Court, both parties recognized that continued litigation would consume significant time, money, and management bandwidth.

Rather than proceeding to a full trial on the merits of infringement and validity, the parties chose a different path. They jointly approached the court under Order XXIII Rule 3 read with Section 151 of the Code of Civil Procedure, seeking to record their amicable settlement and withdraw the suit. Under the terms of the Settlement Agreement, USV agreed to withdraw its invalidity counterclaim against the patents — a significant concession that effectively left AstraZeneca's patent rights intact. In a further gesture of goodwill and finality, USV also agreed to waive the Rs. 5 lakhs in costs that had previously been awarded in its favour in FAO(OS)(COMM) No. 157/2020. The legal friction here was not about who was right on infringement or invalidity — it was about whether the court would accept the settlement as a genuine, binding resolution between the parties.

The Delhi High Court found the settlement to be a genuine amicable resolution between the parties. Allowing the joint application, the court decreed the suit in terms of the settlement. Critically, the court directed that the Settlement Agreement itself would form part of the decree, making it legally binding on both AstraZeneca and USV. By invoking Order XXIII Rule 3 (which governs the compromise of suits) read with Section 151 CPC (which preserves the court's inherent powers), the court gave the settlement the full force of a judicial decree — meaning any breach by either party could be enforced through contempt or execution proceedings.

For founders, startup leaders, and IP professionals, this case delivers a clear and practical lesson: patent infringement suits can be settled at any stage of proceedings, and courts will readily decree the suit in terms of a settlement agreement. By incorporating the settlement into the decree, the court transforms a private contract into a court-enforceable order. If you are negotiating a settlement in an IP dispute, structure your agreement carefully — because once it becomes part of the decree, every clause carries the weight of judicial authority. Whether you are the patent holder or the alleged infringer, a well-drafted settlement can save years of litigation, preserve business relationships, and provide certainty that a courtroom verdict rarely offers.